nonalcoholic steatohepatitis

Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease
Vincent Wai-Sun Wong, Marie Irles, Grace Lai-Hung Wong, Sarah Shili, Anthony Wing-Hung Chan, Wassil Merrouche, Sally She-Ting Shu, Juliette Foucher, Brigitte Le Bail, Wah Kheong Chan, Henry Lik-Yuen Chan, Victor de Ledinghen

Gut Nov 2019, 68 (11) 2057-2064; DOI: 10.1136/gutjnl-2018-317334
Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease
Cyrielle Caussy, Veeral H Ajmera, Puneet Puri, Cynthia Li-Shin Hsu, Shirin Bassirian, Mania Mgdsyan, Seema Singh, Claire Faulkner, Mark A Valasek, Emily Rizo, Lisa Richards, David A Brenner, Claude B Sirlin, Arun J Sanyal, Rohit Loomba

Gut Oct 2019, 68 (10) 1884-1892; DOI: 10.1136/gutjnl-2018-317584
Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study
Yoosoo Chang, Seungho Ryu, Ki-Chul Sung, Yong Kyun Cho, Eunju Sung, Han-Na Kim, Hyun-Suk Jung, Kyung Eun Yun, Jiin Ahn, Hocheol Shin, Sarah Helen Wild, Christopher D Byrne

Gut Sep 2019, 68 (9) 1667-1675; DOI: 10.1136/gutjnl-2018-317666
Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease
Huikuan Chu, Yi Duan, Ling Yang, Bernd Schnabl

Gut Feb 2019, 68 (2) 359-370; DOI: 10.1136/gutjnl-2018-316307
Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
Samar H Ibrahim, Petra Hirsova, Gregory J Gores

Gut May 2018, 67 (5) 963-972; DOI: 10.1136/gutjnl-2017-315691
Lipid-rich environment: a key role promoting carcinogenesis in obesity-related non-alcoholic fatty liver disease
Patricia Aspichueta

Gut Aug 2018, 67 (8) 1376-1377; DOI: 10.1136/gutjnl-2018-316047
Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD
Na Jiao, Susan S Baker, Adrian Chapa-Rodriguez, Wensheng Liu, Colleen A Nugent, Maria Tsompana, Lucy Mastrandrea, Michael J Buck, Robert D Baker, Robert J Genco, Ruixin Zhu, Lixin Zhu

Gut Oct 2018, 67 (10) 1881-1891; DOI: 10.1136/gutjnl-2017-314307
miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression
Geula Hanin, Nadav Yayon, Yonat Tzur, Rotem Haviv, Estelle R Bennett, Shiran Udi, Yoganathan R Krishnamoorthy, Eleni Kotsiliti, Rivka Zangen, Ben Efron, Joseph Tam, Orit Pappo, Eyal Shteyer, Eli Pikarsky, Mathias Heikenwalder, David S Greenberg, Hermona Soreq

Gut Jun 2018, 67 (6) 1124-1134; DOI: 10.1136/gutjnl-2016-312869
Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease
Yaron Rotman, Arun J Sanyal

Gut Jan 2017, 66 (1) 180-190; DOI: 10.1136/gutjnl-2016-312431
Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus
Kenneth Cusi

Gut Jul 2018, 67 (7) 1371; DOI: 10.1136/gutjnl-2017-313958

Main menu

nonalcoholic steatohepatitis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

nonalcoholic steatohepatitis

Pages